ALCON RECEIVES APPROVAL OF RETAANE SUSPENSION IN AUSTRALIA

Alcon, Inc. (NYSE:ACL) announced today that the Australian Therapeutic Goods Administration (TGA) has approved RETAANE(R) suspension (15mg anecortave acetate suspension) for the treatment of subfoveal choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD) where there is a classic component.

Houston Chronicle (http://www.chron.com/disp/story.mpl/prn/texas/3520066.html)